ArticleNutrition & metabolism2026
Association between metabolic score for insulin resistance and risk of cardiometabolic multimorbidity: an analysis based on two national prospective cohorts.
Article in Nutrition & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiometabolic multimorbidity (CMM) has become a major global health concern, carrying substantial mortality risk. This study investigated the association between the metabolic score for insulin resistance (METS-IR) and the incidence of CMM.
methodsThis prospective analysis utilized data from two nationally representative cohorts (CHARLS and ELSA). The association between the baseline METS-IR and incident CMM was assessed using logistic regression models. Restricted cubic splines and subgroup analyses were employed to examine the relationship pattern and consistency.
resultsIn the follow-up period, there were 149 cases of CMM in CHARLS and 287 cases in ELSA. Every unit increase in METS-IR correlated with a 4% elevated risk of CMM in both groups. Individuals in the highest METS-IR quartile exhibited a more than threefold elevation in CMM risk compared with those in the lowest quartile. A linear dose-response relationship was identified, exhibiting similar relationships across the majority of categories, albeit influenced by hypertension and chronic lung disease status.
conclusionIn CHARLS and ELSA, elevated baseline METS-IR independently predicted higher incident CMM risk in midlife and older adults, with a linear dose-response. As a routine-test-based metric, METS-IR can support early high-risk screening for targeted prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.